|
|
Post by Clement on Feb 13, 2019 10:57:40 GMT -5
I am creating this thread for info about BluHale. Most of the info is previously posted, but I wanted to have it in one location.
|
|
|
|
BluHale
Feb 13, 2019 11:00:34 GMT -5
Post by Clement on Feb 13, 2019 11:00:34 GMT -5
|
|
|
|
Post by Clement on Feb 13, 2019 11:02:06 GMT -5
|
|
|
|
BluHale
Feb 13, 2019 11:05:29 GMT -5
Post by Clement on Feb 13, 2019 11:05:29 GMT -5
|
|
|
|
Post by Clement on Feb 13, 2019 11:11:25 GMT -5
|
|
|
|
BluHale
Feb 13, 2019 11:14:44 GMT -5
Post by Clement on Feb 13, 2019 11:14:44 GMT -5
|
|
|
|
Post by mnholdem on Feb 13, 2019 12:56:51 GMT -5
"The devices and method can also be used to monitor the performance of the inhalation systems, for example, detection of the dose being deliver; quantification of the drug being delivered, duration of discharge of a dose being delivered; number of doses administered to the subject, and to monitor the mechanical integrity of the inhalation system." It seems to me that, if combined with a CMG / software that inputs dosage information, patients could have a graphical display of a quantitative dose-to-result performance. Every person with diabetes has her/her own unique profile due to how his or her body responds to insulin. Combine BluHale with a programmable entry or memory chip and you'd have a tool that would recommend dosage based on past performance gathered via BlueTooth. That would be a killer app!  |
|
|
|
Post by goyocafe on Feb 13, 2019 14:09:38 GMT -5
"The devices and method can also be used to monitor the performance of the inhalation systems, for example, detection of the dose being deliver; quantification of the drug being delivered, duration of discharge of a dose being delivered; number of doses administered to the subject, and to monitor the mechanical integrity of the inhalation system." It seems to me that, if combined with a CMG / software that inputs dosage information, patients could have a graphical display of a quantitative dose-to-result performance. Every person with diabetes has her/her own unique profile due to how his or her body responds to insulin. Combine BluHale with a programmable entry or memory chip and you'd have a tool that would recommend dosage based on past performance gathered via BlueTooth. That would be a killer app! Great thinking. Two thumbs up. Imagine Eversense adding in a vibration alert that encourages a patient to check their app and right there on the display is a dosing recommendation for 4, 8, or 12 units of Afrezza using all that data previously collected. |
|
|
|
Post by boca1girl on Feb 13, 2019 14:24:15 GMT -5
"The devices and method can also be used to monitor the performance of the inhalation systems, for example, detection of the dose being deliver; quantification of the drug being delivered, duration of discharge of a dose being delivered; number of doses administered to the subject, and to monitor the mechanical integrity of the inhalation system." It seems to me that, if combined with a CMG / software that inputs dosage information, patients could have a graphical display of a quantitative dose-to-result performance. Every person with diabetes has her/her own unique profile due to how his or her body responds to insulin. Combine BluHale with a programmable entry or memory chip and you'd have a tool that would recommend dosage based on past performance gathered via BlueTooth. That would be a killer app! Great thinking. Two thumbs up. Imagine Eversense adding in a vibration alert that encourages a patient to check their app and right there on the display is a dosing recommendation for 4, 8, or 12 units of Afrezza using all that data previously collected. Someone needs to submit your combined ideas to MNKD management. Hopefully they’ve already thought this out. |
|
|
|
Post by porkini on Feb 13, 2019 14:30:01 GMT -5
|
|
|
|
Post by sportsrancho on Feb 13, 2019 14:35:05 GMT -5
Great thinking. Two thumbs up. Imagine Eversense adding in a vibration alert that encourages a patient to check their app and right there on the display is a dosing recommendation for 4, 8, or 12 units of Afrezza using all that data previously collected. Someone needs to submit your combined ideas to MNKD management. Hopefully they’ve already thought this out. I doubt it, and yes that would be a great idea along with this one .... Too bad MNKD doesn't partner with NVAX on a TS delivery system for NanoFlu. Technovax isn't even in P 1 for this pipeline. As we know it takes a lot of money = dilution to get through P3 and FDA approval. RSV would be off the table with current committments Read more: mnkd.proboards.com/user/950/recent#ixzz5fRR0C2nG |
|
|
|
Post by mnholdem on Feb 13, 2019 17:35:38 GMT -5
I've forwarded several suggestions to management over the years and (humbly) I'm not a rookie Unfortunately, MannKind's budget limits them to what one CEO described as "value-added" activities. I completely understand their need to prioritize where they sink their $ even though I didn't always agree with their rationale on some things. I don't think CEO Castagna did either and, even though I think he way over spent on his questionable executive staff, he seems determined to spend $ where he thinks MannKind will realize the largest ROI. I can respect that. Big Pharma companies have the luxury of experimenting with many ideas in the hope that one or two of them will succeed. MannKind doesn't have that luxury. Perhaps some day they will. |
|
|
|
Post by lennymnkd on Feb 13, 2019 18:01:00 GMT -5
This idea can easily be discussed at the annual shareholders meeting / and should be ... perfect environment for having the opportunity to run this by the top brass . Winner
|
|
